The stratified win statistics (win ratio, win odds, and net benefit)
The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p‐values and powers, because the Z‐values of their statisti...
Saved in:
Published in | Pharmaceutical statistics : the journal of the pharmaceutical industry Vol. 22; no. 4; pp. 748 - 756 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Inc
01.07.2023
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p‐values and powers, because the Z‐values of their statistical tests are approximately equal. Thus, they can complement one another to show the strength of a treatment effect. In this article, we show that the estimated variances of the win statistics are also directly related regardless of ties or indirectly related through ties. Since its introduction in 2018, the stratified win ratio has been applied in designs and analyses of clinical trials, including Phase III and Phase IV studies. This article generalizes the stratified method to the win odds and the net benefit. As a result, the relations of the three win statistics and the approximate equivalence of their statistical tests also hold for the stratified win statistics. |
---|---|
AbstractList | The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p-values and powers, because the Z-values of their statistical tests are approximately equal. Thus, they can complement one another to show the strength of a treatment effect. In this article, we show that the estimated variances of the win statistics are also directly related regardless of ties or indirectly related through ties. Since its introduction in 2018, the stratified win ratio has been applied in designs and analyses of clinical trials, including Phase III and Phase IV studies. This article generalizes the stratified method to the win odds and the net benefit. As a result, the relations of the three win statistics and the approximate equivalence of their statistical tests also hold for the stratified win statistics. Abstract The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p ‐values and powers, because the Z‐values of their statistical tests are approximately equal. Thus, they can complement one another to show the strength of a treatment effect. In this article, we show that the estimated variances of the win statistics are also directly related regardless of ties or indirectly related through ties. Since its introduction in 2018, the stratified win ratio has been applied in designs and analyses of clinical trials, including Phase III and Phase IV studies. This article generalizes the stratified method to the win odds and the net benefit. As a result, the relations of the three win statistics and the approximate equivalence of their statistical tests also hold for the stratified win statistics. The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same null hypothesis of equal win probabilities between two groups. They provide similar p‐values and powers, because the Z‐values of their statistical tests are approximately equal. Thus, they can complement one another to show the strength of a treatment effect. In this article, we show that the estimated variances of the win statistics are also directly related regardless of ties or indirectly related through ties. Since its introduction in 2018, the stratified win ratio has been applied in designs and analyses of clinical trials, including Phase III and Phase IV studies. This article generalizes the stratified method to the win odds and the net benefit. As a result, the relations of the three win statistics and the approximate equivalence of their statistical tests also hold for the stratified win statistics. |
Author | Dong, Gaohong Huang, Bo Wang, Duolao Cheng, Yu Hoaglin, David C. Cui, Ying Gamalo‐Siebers, Margaret |
Author_xml | – sequence: 1 givenname: Gaohong orcidid: 0000-0002-9848-1329 surname: Dong fullname: Dong, Gaohong email: gaohong.dong@beigene.com organization: BeiGene – sequence: 2 givenname: David C. orcidid: 0000-0003-1336-181X surname: Hoaglin fullname: Hoaglin, David C. organization: UMass Chan Medical School – sequence: 3 givenname: Bo orcidid: 0000-0002-3088-9328 surname: Huang fullname: Huang, Bo organization: Pfizer Inc – sequence: 4 givenname: Ying surname: Cui fullname: Cui, Ying organization: Emory University – sequence: 5 givenname: Duolao surname: Wang fullname: Wang, Duolao organization: Liverpool School of Tropical Medicine – sequence: 6 givenname: Yu surname: Cheng fullname: Cheng, Yu organization: University of Pittsburgh – sequence: 7 givenname: Margaret orcidid: 0000-0003-2428-3298 surname: Gamalo‐Siebers fullname: Gamalo‐Siebers, Margaret organization: Pfizer Inc |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36808217$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kFtLwzAYhoNM3EHBXyAFbyasM-c0lzKPMFBwXoemSbCjS2fTMvbvbbc5QfDqy8v38PDlHYKeL70F4BLBKYIQ365DPcVYkhMwQIzIGHGEe8c3pH0wDGEJIRKJZGegT3gCE4zEANwvPm0U6iqtc5dbE21y38Y2hTrPQjTucrcsJ7tVaUyYRKk3kbd1pK23Lq9vzsGpS4tgLw5zBD4eHxaz53j--vQyu5vHGaGSxJQLrjNtEi0R5ZwSjTIqpSUGcupSYQUzTGOqnUiMhNwRYRwzUAroUuYgGYHx3ruuyq_Ghlqt8pDZoki9LZugsGj_JzhMaIte_0GXZVP59jqFE8KIYIjgX2FWlSFU1ql1la_SaqsQVF2zqm1Wdc226NVB2OiVNUfwp8oWiPfAJi_s9l-Rentf7ITfcO6Bkg |
CitedBy_id | crossref_primary_10_1080_19466315_2024_2365629 crossref_primary_10_1002_sim_10140 crossref_primary_10_1016_j_jchf_2023_05_010 crossref_primary_10_1080_10543406_2023_2210658 |
Cites_doi | 10.1080/10543406.2020.1757690 10.1002/pst.2086 10.1016/j.cct.2022.107040 10.1002/pst.1763 10.1002/pst.2251 10.1177/0962280220942558 10.1016/S0140-6736(03)14282-1 10.1007/s43441-022-00420-1 10.1002/sim.8967 10.1080/03610918.2020.1720735 10.1002/sim.3923 10.1038/s41591-021-01659-1 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7 10.1080/10543406.2020.1757692 10.1080/19466315.2019.1575279 10.1080/10543406.2022.2141769 10.1111/biom.12954 10.1080/10543406.2017.1397007 10.1093/eurheartj/ehr352 10.1198/tast.2010.08121 10.32614/CRAN.package.WINS 10.2307/3001666 10.1016/S0140-6736(21)01203-4 10.1002/sim.9570 |
ContentType | Journal Article |
Copyright | 2023 John Wiley & Sons Ltd. 2023 John Wiley & Sons, Ltd. |
Copyright_xml | – notice: 2023 John Wiley & Sons Ltd. – notice: 2023 John Wiley & Sons, Ltd. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. 7X8 |
DOI | 10.1002/pst.2293 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1539-1612 |
EndPage | 756 |
ExternalDocumentID | 10_1002_pst_2293 36808217 PST2293 |
Genre | shortCommunication Journal Article |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1L6 1OC 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACPOU ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HF~ HGLYW HHZ HVGLF HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 NF~ O66 O9- OIG P2P P2W P2X P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 SUPJJ SV3 UB1 W8V W99 WBKPD WIH WIK WJL WOHZO WQJ WRC WXSBR WYISQ XBAML XG1 XV2 ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. 7X8 |
ID | FETCH-LOGICAL-c3493-4676bcbd8b9146643b1c499e3d064fa7e75d5b24bf78d906f37df5d0970fa5f03 |
IEDL.DBID | DR2 |
ISSN | 1539-1604 |
IngestDate | Sat Aug 17 01:09:26 EDT 2024 Thu Oct 10 18:53:03 EDT 2024 Wed Oct 16 15:30:59 EDT 2024 Wed Oct 16 00:39:17 EDT 2024 Sat Aug 24 00:57:26 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | win ratio mantel-Haenszel method Finkelstein-Schoenfeld test net benefit generalized pairwise comparisons win odds |
Language | English |
License | 2023 John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3493-4676bcbd8b9146643b1c499e3d064fa7e75d5b24bf78d906f37df5d0970fa5f03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-2428-3298 0000-0003-1336-181X 0000-0002-3088-9328 0000-0002-9848-1329 |
PMID | 36808217 |
PQID | 2835375132 |
PQPubID | 1036354 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2778976084 proquest_journals_2835375132 crossref_primary_10_1002_pst_2293 pubmed_primary_36808217 wiley_primary_10_1002_pst_2293_PST2293 |
PublicationCentury | 2000 |
PublicationDate | July/August 2023 2023 Jul-Aug 2023-07-00 20230701 |
PublicationDateYYYYMMDD | 2023-07-01 |
PublicationDate_xml | – month: 07 year: 2023 text: July/August 2023 |
PublicationDecade | 2020 |
PublicationPlace | Chichester, UK |
PublicationPlace_xml | – name: Chichester, UK – name: England – name: Macclesfield |
PublicationTitle | Pharmaceutical statistics : the journal of the pharmaceutical industry |
PublicationTitleAlternate | Pharm Stat |
PublicationYear | 2023 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2018; 28 2010; 64 2021; 20 2023; 22 2019; 75 2022 2020; 30 2010; 29 1999; 18 2022; 51 2023; 124 1954; 10 2022; 56 2022; 41 2020; 12 2021; 397 2021; 30 2012; 33 2016; 15 2021; 40 2022; 28 2003; 362 e_1_2_10_12_1 e_1_2_10_23_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_24_1 e_1_2_10_10_1 e_1_2_10_21_1 e_1_2_10_11_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_25_1 e_1_2_10_7_1 e_1_2_10_15_1 |
References_xml | – volume: 28 start-page: 568 issue: 3 year: 2022 end-page: 574 article-title: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial publication-title: Nat Med – volume: 15 start-page: 430 issue: 5 year: 2016 end-page: 437 article-title: Is the asymptotic variance estimator of the logarithm of the win ratio under the null hypothesis sound? – A note on the generalized analytic solution to the win ratio by Dong et al. (2016). Supporting information #7 (a post‐publishing note) to Dong et al. (2016) publication-title: Pharmaceut Stat – volume: 33 start-page: 176 issue: 2 year: 2012 end-page: 182 article-title: The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities publication-title: Eur Heart J – volume: 51 start-page: 3645 issue: 7 year: 2022 end-page: 3659 article-title: Optimal weighted estimation versus Cochran–mantel–Haenszel publication-title: Commun Stat – Simulat Comput – volume: 30 start-page: 941 issue: 5 year: 2020 end-page: 946 article-title: The use of the win odds in the design of non‐inferiority clinical trials publication-title: J Biopharm Stat – volume: 40 start-page: 3367 issue: 14 year: 2021 end-page: 3384 article-title: Win odds: an adaptation of the win ratio to include ties publication-title: Stat Med – volume: 30 start-page: 580 issue: 2 year: 2021 end-page: 611 article-title: Adjusted win ratio with stratification: calculation methods and interpretation publication-title: Stat Methods Med Res – volume: 124 year: 2023 article-title: Statistical power considerations in the use of win ratio in cardiovascular outcome trials publication-title: Contemp Clin Trials – volume: 64 start-page: 121 issue: 2 year: 2010 end-page: 130 article-title: Rank‐based analyses of stratified experiments: alternatives to the van Elteren test publication-title: Am Stat – volume: 397 start-page: 2253 issue: 10291 year: 2021 end-page: 2263 article-title: ACTION coalition COVID‐19 Brazil IV investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID‐19 and elevated D‐dimer concentration (ACTION): an open‐label, multicentre, randomised, controlled trial publication-title: Lancet – volume: 20 start-page: 440 issue: 3 year: 2021 end-page: 450 article-title: Adjustingwin statistics for dependent censoring publication-title: Pharm Stat – volume: 18 start-page: 1341 year: 1999 end-page: 1354 article-title: Combining mortality and longitudinal measures in clinical trials publication-title: Stat Med – volume: 12 start-page: 99 issue: 1 year: 2020 end-page: 106 article-title: The win ratio: on interpretation and handling of ties publication-title: Statist Biopharm Res – start-page: 1 year: 2022 end-page: 17 article-title: Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials publication-title: J Biopharm Stat – volume: 362 start-page: 759 year: 2003 end-page: 766 article-title: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM‐overall programme publication-title: Lancet – volume: 29 start-page: 3245 issue: 30 year: 2010 end-page: 3257 article-title: Generalized pairwise comparisons of prioritized outcomes in the two‐sample problem publication-title: Stat Med – volume: 56 start-page: 785 issue: 5 year: 2022 end-page: 794 article-title: Design and analysis of studies based on hierarchical composite endpoints: insights from the DARE‐19 trial publication-title: Ther Innov Regul Sci – volume: 75 start-page: 347 issue: 1 year: 2019 end-page: 351 article-title: On the alternative hypotheses for the win ratio publication-title: Biometrics – volume: 10 start-page: 101 year: 1954 end-page: 129 article-title: The combination of estimates from different experiments publication-title: Biometrics – volume: 41 start-page: 5305 year: 2022 end-page: 5318 article-title: Stratified proportional win‐fractions regression analysis publication-title: Stat Med – volume: 30 start-page: 882 issue: 5 year: 2020 end-page: 899 article-title: The inverse‐probability‐of‐censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring publication-title: J Biopharm Stat – volume: 28 start-page: 778 issue: 4 year: 2018 end-page: 796 article-title: The stratified win ratio publication-title: J Biopharm Stat – volume: 22 start-page: 20 issue: 1 year: 2023 end-page: 33 article-title: Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time‐to‐event outcomes publication-title: Pharm Stat – ident: e_1_2_10_18_1 doi: 10.1080/10543406.2020.1757690 – ident: e_1_2_10_25_1 doi: 10.1002/pst.2086 – ident: e_1_2_10_13_1 doi: 10.1016/j.cct.2022.107040 – ident: e_1_2_10_12_1 doi: 10.1002/pst.1763 – ident: e_1_2_10_9_1 doi: 10.1002/pst.2251 – ident: e_1_2_10_22_1 doi: 10.1177/0962280220942558 – ident: e_1_2_10_17_1 doi: 10.1016/S0140-6736(03)14282-1 – ident: e_1_2_10_20_1 doi: 10.1007/s43441-022-00420-1 – ident: e_1_2_10_19_1 doi: 10.1002/sim.8967 – ident: e_1_2_10_11_1 doi: 10.1080/03610918.2020.1720735 – ident: e_1_2_10_3_1 doi: 10.1002/sim.3923 – ident: e_1_2_10_7_1 doi: 10.1038/s41591-021-01659-1 – ident: e_1_2_10_2_1 doi: 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7 – ident: e_1_2_10_24_1 doi: 10.1080/10543406.2020.1757692 – ident: e_1_2_10_5_1 doi: 10.1080/19466315.2019.1575279 – ident: e_1_2_10_16_1 doi: 10.1080/10543406.2022.2141769 – ident: e_1_2_10_14_1 doi: 10.1111/biom.12954 – ident: e_1_2_10_6_1 doi: 10.1080/10543406.2017.1397007 – ident: e_1_2_10_4_1 doi: 10.1093/eurheartj/ehr352 – ident: e_1_2_10_21_1 doi: 10.1198/tast.2010.08121 – ident: e_1_2_10_10_1 doi: 10.32614/CRAN.package.WINS – ident: e_1_2_10_15_1 doi: 10.2307/3001666 – ident: e_1_2_10_8_1 doi: 10.1016/S0140-6736(21)01203-4 – ident: e_1_2_10_23_1 doi: 10.1002/sim.9570 |
SSID | ssj0017895 |
Score | 2.370634 |
Snippet | The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test the same... Abstract The win odds and the net benefit are related directly to each other and indirectly, through ties, to the win ratio. These three win statistics test... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 748 |
SubjectTerms | Finkelstein‐Schoenfeld test generalized pairwise comparisons Humans mantel–Haenszel method net benefit Odds Ratio Probability Statistical analysis win odds win ratio |
Title | The stratified win statistics (win ratio, win odds, and net benefit) |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpst.2293 https://www.ncbi.nlm.nih.gov/pubmed/36808217 https://www.proquest.com/docview/2835375132 https://search.proquest.com/docview/2778976084 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA6yJ1-8X-aNCDIU1q1tkiZ9FC-IoAydIPhQmhsMoRuuQ-av96RZN1QE8amUpEmbc8k56TnfQehEMM0TI1WghDutYrkMUiZNECtgDqq5VNQlON_dJzdP9PaZPc-iKl0ujMeHmB-4Ocmo9LUT8FyOuwvQ0NG47MSwWYH6jQh30VyXD3PkqIiLquAKyHMaRElIa9zZMO7WD37diX6Yl1-t1Wq7uV5FL_WL-iiT186klB318Q3D8X9fsoZWZlYoPvdss46WTLGBWj0PYz1t4_4iK2vcxi3cWwBcTzfRJTRjj7drwYLF74MCu8Qkj_mMT919xVjtqmmoNQySFxoXpsQSlKsdlGdb6On6qn9xE8yqMQSK0JQEoFETqaQWMo0cJj2RkQJ3yRANVo3NueFMMxlTabnQaZhYwrVlOkx5aHNmQ7KNGsWwMLsIc2G14EJxQnNw0JhQNDJahSQ3qQIbqImOa8pkIw-6kXl45TiDxcrcYjXRQU2ybCZ248yBxxHOwMOGIebNIDDuL0hemOEE-nDgDZ6EgjbRjif1fBLiCpGAk9ZErYpgv86e9R777rr31477aNkVqveBvgeoUb5NzCGYM6U8qhj3E4aq8Ks |
link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-67qF7Wbd2H-naVYUSOohT25IsmT6NdSX9JHQp9KFgrC8oA6c0DqX763ey4oR2DMaejJEs2bo76Xey7ncAu5IbkVmlIy39bhUvVZRzZaNUo3IwI5RmPsD5_CIbXLGTa369BAdtLEzgh5hvuHnLaOZrb-B-Q3p_wRp6N6n7Ka5WL-AlWjv1eRsOL-fcUYmQTcoVtOg8SrKYtcyzcbrfPvl0LfoDYD7Fq82Cc7QKN-2rhnMmP_vTWvX1r2csjv_5LW_g9QyIkq9Bc97Ckq3WoDsMTNaPPTJaBGZNeqRLhguO68d1OMRiEih3HYJY8nBbER-bFGifyZ6_b3Sr1xSNjcFGysqQytZE4fzqbusv7-Dq6Pvo2yCaJWSINGU5jXCYM6WVkSpPPC09VYlGj8lSg8DGlcIKbrhKmXJCmjzOHBXGcRPnInYldzF9D8vVuLIfgQjpjBRSC8pK9NG41CyxRse0tLlGGNSBnVY0xV3g3SgCw3Ja4GAVfrA6sNnKrJhZ3qTw_HFUcHSysYl5MdqM_xFSVnY8xToClUNksWQd-BBkPe-E-lwk6Kd1oNtI7K-9F8MfI3_d-NeK27AyGJ2fFWfHF6ef4JXPWx_O_W7Ccn0_tVuIbmr1udHi34Zm9MM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9swED-6Dka_rN2rS58ajLBBnNqWZMkfS9vQ7lHClkJhH4z1glJwQuNQ2r--JytO6Eah7JMxkiVbdyf9Ttb9DuCz5EZkVulIS79bxUsV5VzZKNWoHMwIpZkPcP55np1esG-X_HJ-qtLHwgR-iMWGm7eMZr72Bj4x7mBJGjqZ1v0UF6sX8JJlCHw9IPq1oI5KhGwyrqBB51GSxawlno3Tg_bJx0vRP_jyMVxt1pvBOvxp3zQcM7nuz2rV1_d_kTj-36dswOs5DCWHQW_ewIqt3kJ3GHis73pktAzLmvZIlwyXDNd37-AYi0kg3HUIYcntVUV8ZFIgfSZf_H2jWb2maGwMNlJWhlS2JgpnV3dVf30PF4OT0dFpNE_HEGnKchrhlJoprYxUeeJJ6alKNPpLlhqENa4UVnDDVcqUE9LkceaoMI6bOBexK7mL6QdYrcaV_QhESGekkFpQVqKHxqVmiTU6pqXNNYKgDnxqJVNMAutGEfiV0wIHq_CD1YGdVmTF3O6mhWePo4Kji41NLIrRYvxvkLKy4xnWEagbIosl68BmEPWiE-ozkaCX1oFuI7Aney-Gv0f-uvXcivvwang8KH6cnX_fhjWftD4c-t2B1fpmZncR2tRqr9HhB7Zv83I |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+stratified+win+statistics+%28win+ratio%2C+win+odds%2C+and+net+benefit%29&rft.jtitle=Pharmaceutical+statistics+%3A+the+journal+of+the+pharmaceutical+industry&rft.au=Dong%2C+Gaohong&rft.au=Hoaglin%2C+David+C&rft.au=Huang%2C+Bo&rft.au=Cui%2C+Ying&rft.date=2023-07-01&rft.eissn=1539-1612&rft.volume=22&rft.issue=4&rft.spage=748&rft.epage=756&rft_id=info:doi/10.1002%2Fpst.2293&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1539-1604&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1539-1604&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1539-1604&client=summon |